Received Apr 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | — | — |
HCP called to report a female patient received third dose of GARDASIL 9 late according to vaccination schedule. Caller did not have exact dates but states the first and second dose were administered appropriately according to the vaccination schedule; No additional AE; This spontaneous report was received from a nurse and refers to a female patient of unknown age. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unknown date, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (expiration date, and lot # were not reported) for prophylaxis. According to the reporter, the first and second dose were administered appropriately according to the vaccination schedule, but the third dose was administered later than the recommended 6 months (the nurse did not have exact dates) (Inappropriate schedule of product administration). No adverse events were reported. Lot is being requested and will be submitted if received.